Advertisement

Topics

Avelumab Falls Short in Phase III NSCLC Trial

15:34 EST 15 Feb 2018 | OncLive

Avelumab (Bavencio) missed the primary endpoint of improving overall survival in pretreated patients with non–small cell lung cancer, according to findings from the phase III JAVELIN Lung 200 Trial. 

Original Article: Avelumab Falls Short in Phase III NSCLC Trial

NEXT ARTICLE

More From BioPortfolio on "Avelumab Falls Short in Phase III NSCLC Trial"

Advertisement

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters here: Contact BioPortfolio.
All rights reserved. All other trademarks recognized. Copyright © 1997-2018 BioPortfolio Limited. Site developed by Alacrify Ltd.